NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

NeuroOne Medical Technologies (NMTC) reported successful large-animal procedures using its StereoCED platform for drug delivery and electrophysiological monitoring. The company expects to launch human clinical studies this quarter and recognize related revenue in fiscal Q4 2026. The procedures were conducted at the University of Minnesota, demonstrating technical feasibility and validating the integrated surgical and drug delivery workflow.

NeuroOne Medical Technologies reported Q3 2026 revenue up 16%, driven by demand for its OneRF Brain Ablation System, though recognized revenue was limited by manufacturing lead times. Gross margin rose to 59.9%. Management cited ISO 13485 certification, guidance of $9.2M to $10.5M for FY2026, and a second manufacturing site expected in early 2027.

NeuroOne Medical Technologies (Nasdaq: NMTC) reported fiscal Q3 2026 results for the quarter ended June 30, 2026. Product revenue rose 16% YoY to $2.0M and product gross margins expanded to 59.9%. New product orders were $2.7M, lifting backlog to $1.7M, and FY2026 orders totaled $11.2M. The company also cited ISO 13485 certification and updates on StereoCED and OneRF platforms.

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9% $2.7 Million in Product Orders Outpace Shipments of $2.0 Million Company Has Received Product Orders for Fiscal Year 2026 of $11.2 Million; Wo

AppFolio (APPF) reported Q3 2026 revenue of $296M, up 19% YoY. CEO Shane Trigg noted non-GAAP operating income was 27.3% of revenue and GAAP operating income was 19.4%. The company anticipates 2026 revenue between $1.122B and $1.127B with a non-GAAP operating margin of 26.5%-27.5%.

Banner Corp (BANR) reported Q3 2026 core earnings of $68.6M, up 1% YoY, with revenue increasing 6% to $179M. Organic loan growth was 8% annualized, driven by commercial real estate. EPS decreased to $1.36 from $1.54 due to merger expenses. The Pacific Financial acquisition added $766M in loans and $1B in deposits. Loan growth may face headwinds from rising interest rates. Net interest margin expansion is expected in Q4, with future trajectory dependent on Fed actions.